Jump Financial’s Nurix Therapeutics NRIX Stock Holding History

Jump Financial’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.39M	Buy	89,518 +9,481	+12%	+$157K	0.02%	797
2025 Q4	$1.52M	Buy	+80,037	New	+$1.15M	0.02%	804
2025 Q2	–	Sell	-76,060	Closed	-$904K	–	2030
2025 Q1	$904K	Buy	76,060 +1,441	+2%	+$24.1K	0.01%	866
2024 Q4	$1.41M	Buy	+74,619	New	+$1.71M	0.03%	637
2024 Q1	–	Sell	-15,332	Closed	-$158K	–	2166
2023 Q4	$158K	Buy	+15,332	New	+$105K	0.01%	1609
2023 Q2	–	Sell	-12,100	Closed	-$107K	–	2047
2023 Q1	$107K	Sell	12,100 -13,173	-52%	-$137K	﹤0.01%	1431
2022 Q4	$277K	Sell	25,273 -18,527	-42%	-$223K	0.01%	1093
2022 Q3	$571K	Buy	43,800 +5,800	+15%	+$91.8K	0.02%	838
2022 Q2	$481K	Buy	38,000 +5,837	+18%	+$66.2K	0.02%	870
2022 Q1	$451K	Buy	+32,163	New	+$571K	0.02%	862

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jump Financial's NRIX Position: Q1 2026 in Review

Jump Financial increased its Nurix Therapeutics (NRIX) stake by 12% in Q1 2026, buying an estimated $157K and bringing the position to 89,518 shares worth $1.39M. The position accounts for 0.02% of the portfolio, ranked #797.

Jump Financial first reported a position in NRIX in Q1 2022 and has held it in 10 quarters since. The position peaked at $1.52M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Jump Financial held 89,518 shares of Nurix Therapeutics worth $1.39M as of Q1 2026.
Jump Financial bought 9,481 Nurix Therapeutics shares in Q1 2026, an estimated $157K.
Nurix Therapeutics made up 0.02% of Jump Financial's portfolio in Q1 2026, its #797 holding.
Jump Financial first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 10 quarters since.
Jump Financial's Nurix Therapeutics position peaked at $1.52M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.